New pill tested for Tough-to-Treat lung cancer
Disease control
Terminated
This early-stage study tested a new oral drug called TRX-221 for people with advanced lung cancer driven by an EGFR gene mutation, whose disease worsened after standard treatments. The main goals were to find a safe dose and see if the drug could shrink tumors. The trial was term…
Phase: PHASE1, PHASE2 • Sponsor: Therapex Co., Ltd • Aim: Disease control
Last updated Apr 04, 2026 09:35 UTC